---
title: "Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study"
date: "2025-02-11 01:05:59"
summary: "Grace Therapeutics&#39; GTx-104 met its Phase 3 trial endpoint, showing clinical benefits over oral nimodipine. US NDA submission is expected in early 2025."
categories:
  - "benzinga"
lang:
  - "en"
translations:
  - "en"
tags:
  - "benzinga"
menu: ""
thumbnail: "https://www.benzinga.com/files/images/story/2025/02/10/GRCE.png"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Grace Therapeutics' GTx-104 met its Phase 3 trial endpoint, showing clinical benefits over oral nimodipine. US NDA submission is expected in early 2025.

[benzinga](https://www.benzinga.com/general/biotech/25/02/43600505/small-cap-grace-therapeutics-touts-positive-data-from-brain-hemorrhage-study)
